Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Testing av nivolumab med eller uten ipilimumab i mangelfullt mismatch reparasjonssystem (dMMR) tilbakevendende endometriekarsinom

30. oktober 2026 oppdatert av: National Cancer Institute (NCI)

En randomisert fase II-studie av Nivolumab og Ipilimumab sammenlignet med Nivolumab monoterapi hos pasienter med mangelfullt reparasjonssystem for mismatch Residiverende endometriekarsinom

This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

PRIMARY OBJECTIVE:

I. To assess efficacy in terms of progression-free survival (PFS) for immunotherapy with dual immune checkpoint blockade (nivolumab/ipilimumab) versus (vs.) monotherapy (nivolumab) in patients with recurrent mismatch repair (MMR) deficient endometrial carcinoma with measurable or non-measurable (detectable) disease.

SECONDARY OBJECTIVES:

I. To evaluate the overall survival (OS) as estimated from time of enrollment to last follow-up or death.

II. To evaluate the objective response rate by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 in those with measurable disease at start of treatment.

III. To evaluate progression-free survival at 6 months. IV. To evaluate the nature, frequency and degree of toxicity as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0.

V. To evaluate PFS and objective response rate in patients with prior anti-PD1/PDL1 therapy and compare efficacy of dual immune checkpoint inhibition vs. anti-PD1 monotherapy.

OUTLINE: Patients are randomized into 1 of 2 arms.

ARM I: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or complete response (CR). Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.

ARM II: Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.

MAINTENANCE THERAPY: Patients achieving CR on Arm I or II receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.

Additionally, all patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. All patients also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial.

Patients are followed every 3 months for 2 years, and then, every 6 months for 3 years.

Studietype

Intervensjonell

Registrering (Antatt)

81

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • Alabama
      • Birmingham, Alabama, Forente stater, 35233
        • Rekruttering
        • University of Alabama at Birmingham Cancer Center
        • Hovedetterforsker:
          • Michael D. Toboni
        • Ta kontakt med:
    • Georgia
      • Athens, Georgia, Forente stater, 30607
        • Suspendert
        • University Cancer and Blood Center LLC
      • Augusta, Georgia, Forente stater, 30912
        • Rekruttering
        • Augusta University Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bunja J. Rungruang
    • Idaho
      • Boise, Idaho, Forente stater, 83712
        • Rekruttering
        • Saint Luke's Cancer Institute - Boise
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Boise, Idaho, Forente stater, 83706
        • Suspendert
        • Saint Alphonsus Cancer Care Center-Boise
      • Caldwell, Idaho, Forente stater, 83605
        • Suspendert
        • Saint Alphonsus Cancer Care Center-Caldwell
      • Coeur d'Alene, Idaho, Forente stater, 83814
        • Rekruttering
        • Kootenai Health - Coeur d'Alene
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Fruitland, Idaho, Forente stater, 83619
        • Rekruttering
        • Saint Luke's Cancer Institute - Fruitland
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Meridian, Idaho, Forente stater, 83642
        • Rekruttering
        • Saint Luke's Cancer Institute - Meridian
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Nampa, Idaho, Forente stater, 83687
        • Rekruttering
        • Saint Luke's Cancer Institute - Nampa
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Nampa, Idaho, Forente stater, 83687
        • Suspendert
        • Saint Alphonsus Cancer Care Center-Nampa
      • Post Falls, Idaho, Forente stater, 83854
        • Rekruttering
        • Kootenai Clinic Cancer Services - Post Falls
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Sandpoint, Idaho, Forente stater, 83864
        • Rekruttering
        • Kootenai Clinic Cancer Services - Sandpoint
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60612
        • Suspendert
        • University of Illinois
      • Danville, Illinois, Forente stater, 61832
        • Rekruttering
        • Carle at The Riverfront
        • Hovedetterforsker:
          • Pratima Chalasani
        • Ta kontakt med:
      • Effingham, Illinois, Forente stater, 62401
        • Rekruttering
        • Carle Physician Group-Effingham
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pratima Chalasani
      • Mattoon, Illinois, Forente stater, 61938
        • Rekruttering
        • Carle Physician Group-Mattoon/Charleston
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pratima Chalasani
      • Normal, Illinois, Forente stater, 61761
        • Rekruttering
        • Carle BroMenn Medical Center
        • Hovedetterforsker:
          • Pratima Chalasani
        • Ta kontakt med:
      • Normal, Illinois, Forente stater, 61761
        • Rekruttering
        • Carle Cancer Institute Normal
        • Hovedetterforsker:
          • Pratima Chalasani
        • Ta kontakt med:
      • Urbana, Illinois, Forente stater, 61801
        • Rekruttering
        • Carle Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pratima Chalasani
    • Indiana
      • Carmel, Indiana, Forente stater, 46032
        • Suspendert
        • IU Health North Hospital
      • Crown Point, Indiana, Forente stater, 46307
        • Rekruttering
        • Northwest Cancer Center - Crown Point
        • Hovedetterforsker:
          • Pratima Chalasani
        • Ta kontakt med:
      • Dyer, Indiana, Forente stater, 46311
        • Rekruttering
        • Northwest Oncology LLC
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 219-924-8178
        • Hovedetterforsker:
          • Pratima Chalasani
      • Hobart, Indiana, Forente stater, 46342
        • Rekruttering
        • Northwest Cancer Center - Hobart
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 219-947-1795
        • Hovedetterforsker:
          • Pratima Chalasani
      • Hobart, Indiana, Forente stater, 46342
        • Rekruttering
        • Saint Mary Medical Center
        • Hovedetterforsker:
          • Pratima Chalasani
        • Ta kontakt med:
      • Indianapolis, Indiana, Forente stater, 46202
        • Rekruttering
        • Indiana University/Melvin and Bren Simon Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jessica E. Parker
      • Indianapolis, Indiana, Forente stater, 46312
        • Rekruttering
        • Saint Catherine Hospital
        • Hovedetterforsker:
          • Pratima Chalasani
        • Ta kontakt med:
      • Munster, Indiana, Forente stater, 46321
        • Rekruttering
        • The Community Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 219-836-3349
        • Hovedetterforsker:
          • Pratima Chalasani
      • Munster, Indiana, Forente stater, 46321
        • Rekruttering
        • Women's Diagnostic Center - Munster
        • Ta kontakt med:
        • Hovedetterforsker:
          • Pratima Chalasani
      • Valparaiso, Indiana, Forente stater, 46383
        • Rekruttering
        • Northwest Cancer Center - Valparaiso
        • Hovedetterforsker:
          • Pratima Chalasani
        • Ta kontakt med:
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • Rekruttering
        • University of Iowa/Holden Comprehensive Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-237-1225
        • Hovedetterforsker:
          • David P. Bender
    • Kentucky
      • Louisville, Kentucky, Forente stater, 40202
        • Rekruttering
        • The James Graham Brown Cancer Center at University of Louisville
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 502-562-3429
        • Hovedetterforsker:
          • Jason A. Chesney
      • Louisville, Kentucky, Forente stater, 40245
        • Rekruttering
        • UofL Health Medical Center Northeast
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jason A. Chesney
    • Maine
      • Scarborough, Maine, Forente stater, 04074
        • Rekruttering
        • MaineHealth Maine Medical Center- Scarborough
        • Hovedetterforsker:
          • Leslie S. Bradford
        • Ta kontakt med:
    • Michigan
      • Battle Creek, Michigan, Forente stater, 49017
        • Rekruttering
        • Bronson Battle Creek
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Grand Rapids, Michigan, Forente stater, 49503
        • Suspendert
        • Trinity Health Grand Rapids Hospital
      • Grand Rapids, Michigan, Forente stater, 49503
        • Rekruttering
        • Corewell Health Grand Rapids Hospitals - Butterworth Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Forente stater, 49007
        • Rekruttering
        • Bronson Methodist Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Forente stater, 49007
        • Rekruttering
        • West Michigan Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Kalamazoo, Michigan, Forente stater, 49009
        • Rekruttering
        • Beacon Kalamazoo Cancer Center
        • Hovedetterforsker:
          • Kathleen Y. Butler
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 574-647-7370
      • Muskegon, Michigan, Forente stater, 49444
        • Suspendert
        • Trinity Health Muskegon Hospital
      • Niles, Michigan, Forente stater, 49120
        • Rekruttering
        • Corewell Health Lakeland Hospitals - Niles Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 616-391-1230
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Norton Shores, Michigan, Forente stater, 49444
        • Suspendert
        • Cancer and Hematology Centers of Western Michigan - Norton Shores
      • Reed City, Michigan, Forente stater, 49677
        • Rekruttering
        • Corewell Health Reed City Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Forente stater, 49085
        • Rekruttering
        • Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Saint Joseph, Michigan, Forente stater, 49085
        • Rekruttering
        • Corewell Health Lakeland Hospitals - Saint Joseph Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Traverse City, Michigan, Forente stater, 49684
        • Rekruttering
        • Munson Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
      • Wyoming, Michigan, Forente stater, 49519
        • Rekruttering
        • University of Michigan Health - West
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kathleen Y. Butler
    • Minnesota
      • Coon Rapids, Minnesota, Forente stater, 55433
        • Rekruttering
        • Mercy Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Deer River, Minnesota, Forente stater, 56636
        • Rekruttering
        • Essentia Health - Deer River Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Duluth, Minnesota, Forente stater, 55805
        • Rekruttering
        • Essentia Health Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Duluth, Minnesota, Forente stater, 55805
        • Rekruttering
        • Miller-Dwan Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Edina, Minnesota, Forente stater, 55435
        • Rekruttering
        • Fairview Southdale Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Edina, Minnesota, Forente stater, 55435
        • Rekruttering
        • Minnesota Oncology - Edina
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Hibbing, Minnesota, Forente stater, 55746
        • Rekruttering
        • Essentia Health Hibbing Clinic
        • Hovedetterforsker:
          • Bret E. Friday
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 218-786-3308
      • Minneapolis, Minnesota, Forente stater, 55407
        • Rekruttering
        • Abbott-Northwestern Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Saint Louis Park, Minnesota, Forente stater, 55416
        • Rekruttering
        • Park Nicollet Clinic - Saint Louis Park
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Saint Paul, Minnesota, Forente stater, 55101
        • Rekruttering
        • Regions Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Saint Paul, Minnesota, Forente stater, 55102
        • Rekruttering
        • United Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Sandstone, Minnesota, Forente stater, 55072
        • Rekruttering
        • Essentia Health Sandstone
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Shakopee, Minnesota, Forente stater, 55379
        • Rekruttering
        • Saint Francis Regional Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Adrianne Mallen
      • Virginia, Minnesota, Forente stater, 55792
        • Rekruttering
        • Essentia Health Virginia Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
    • Missouri
      • Columbia, Missouri, Forente stater, 65212
        • Rekruttering
        • MU Health - University Hospital/Ellis Fischel Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 573-882-7440
        • Hovedetterforsker:
          • Arwa M. Mohammad
      • St Louis, Missouri, Forente stater, 63110
        • Rekruttering
        • Washington University School of Medicine
        • Ta kontakt med:
        • Hovedetterforsker:
          • Premal H. Thaker
    • Montana
      • Anaconda, Montana, Forente stater, 59711
        • Rekruttering
        • Community Hospital of Anaconda
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Billings, Montana, Forente stater, 59101
        • Rekruttering
        • Billings Clinic Cancer Center
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Billings, Montana, Forente stater, 59102
        • Rekruttering
        • Saint Vincent Frontier Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-648-6274
        • Hovedetterforsker:
          • Megan Petersen
      • Billings, Montana, Forente stater, 59106
        • Rekruttering
        • Intermountain Health West End Clinic
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 406-238-6685
        • Hovedetterforsker:
          • Megan Petersen
      • Bozeman, Montana, Forente stater, 59715
        • Rekruttering
        • Bozeman Health Deaconess Hospital
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Great Falls, Montana, Forente stater, 59405
        • Rekruttering
        • Benefis Sletten Cancer Institute
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Kalispell, Montana, Forente stater, 59901
        • Rekruttering
        • Logan Health Medical Center
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
      • Missoula, Montana, Forente stater, 59804
        • Rekruttering
        • Community Medical Center
        • Hovedetterforsker:
          • John M. Schallenkamp
        • Ta kontakt med:
    • Nebraska
      • Omaha, Nebraska, Forente stater, 68114
        • Rekruttering
        • Nebraska Methodist Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 402-354-5144
        • Hovedetterforsker:
          • Brent J. Tierney
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89106
        • Rekruttering
        • Women's Cancer Center of Nevada
        • Hovedetterforsker:
          • Nicola M. Spirtos
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 702-851-4672
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • Rekruttering
        • University of New Mexico Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Carolyn Y. Muller
    • New York
      • Buffalo, New York, Forente stater, 14263
        • Aktiv, ikke rekrutterende
        • Roswell Park Cancer Institute
      • Rochester, New York, Forente stater, 14642
        • Rekruttering
        • University of Rochester
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 585-275-5830
        • Hovedetterforsker:
          • Rachael Turner
      • Syracuse, New York, Forente stater, 13210
        • Rekruttering
        • State University of New York Upstate Medical University
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 315-464-5476
        • Hovedetterforsker:
          • Mary J. Cunningham
      • Webster, New York, Forente stater, 14580
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke University Medical Center
        • Hovedetterforsker:
          • Angeles A. Secord
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 888-275-3853
      • Raleigh, North Carolina, Forente stater, 27607
        • Rekruttering
        • Duke Women's Cancer Care Raleigh
        • Hovedetterforsker:
          • Angeles A. Secord
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 919-785-4878
    • North Dakota
      • Fargo, North Dakota, Forente stater, 58103
        • Rekruttering
        • Essentia Health Cancer Center-South University Clinic
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
    • Ohio
      • Beachwood, Ohio, Forente stater, 44122
        • Rekruttering
        • UHHS-Chagrin Highlands Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amy Armstrong
      • Centerville, Ohio, Forente stater, 45459
        • Rekruttering
        • Miami Valley Hospital South
        • Ta kontakt med:
        • Hovedetterforsker:
          • Michael S. Guy
      • Chardon, Ohio, Forente stater, 44024
        • Rekruttering
        • Geauga Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amy Armstrong
      • Cincinnati, Ohio, Forente stater, 45220
        • Aktiv, ikke rekrutterende
        • Good Samaritan Hospital - Cincinnati
      • Cleveland, Ohio, Forente stater, 44195
        • Rekruttering
        • Cleveland Clinic Foundation
        • Ta kontakt med:
        • Hovedetterforsker:
          • Peter G. Rose
      • Cleveland, Ohio, Forente stater, 44106
        • Rekruttering
        • Case Western Reserve University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amy Armstrong
      • Cleveland, Ohio, Forente stater, 44111
        • Rekruttering
        • Cleveland Clinic Cancer Center/Fairview Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Peter G. Rose
      • Columbus, Ohio, Forente stater, 43210
        • Rekruttering
        • Ohio State University Comprehensive Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Floor Backes
      • Mayfield Heights, Ohio, Forente stater, 44124
        • Rekruttering
        • Hillcrest Hospital Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Peter G. Rose
      • Mentor, Ohio, Forente stater, 44060
        • Rekruttering
        • UH Seidman Cancer Center at Lake Health Mentor Campus
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amy Armstrong
      • Parma, Ohio, Forente stater, 44129
        • Rekruttering
        • University Hospitals Parma Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amy Armstrong
      • Westlake, Ohio, Forente stater, 44145
        • Rekruttering
        • UH Seidman Cancer Center at Saint John Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Amy Armstrong
    • Oklahoma
      • Oklahoma City, Oklahoma, Forente stater, 73104
        • Rekruttering
        • University of Oklahoma Health Sciences Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Christina Washington
      • Tulsa, Oklahoma, Forente stater, 74146
        • Aktiv, ikke rekrutterende
        • Oklahoma Cancer Specialists and Research Institute-Tulsa
    • Oregon
      • Ontario, Oregon, Forente stater, 97914
        • Suspendert
        • Saint Alphonsus Cancer Care Center-Ontario
      • Portland, Oregon, Forente stater, 97213
        • Rekruttering
        • Providence Portland Medical Center
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Portland, Oregon, Forente stater, 97225
        • Rekruttering
        • Providence Saint Vincent Medical Center
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
    • Pennsylvania
      • Beaver, Pennsylvania, Forente stater, 15009
        • Rekruttering
        • UPMC-Heritage Valley Health System Beaver
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Butler, Pennsylvania, Forente stater, 16001
        • Rekruttering
        • UPMC Hillman Cancer Center at Butler Health System
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Cranberry Township, Pennsylvania, Forente stater, 16066
        • Rekruttering
        • UPMC Hillman Cancer Center - Passavant - Cranberry
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Erie, Pennsylvania, Forente stater, 16505
        • Rekruttering
        • UPMC Hillman Cancer Center Erie
        • Hovedetterforsker:
          • Alexander B. Olawaiye
        • Ta kontakt med:
      • Farrell, Pennsylvania, Forente stater, 16121
        • Rekruttering
        • UPMC Cancer Center at UPMC Horizon
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Greensburg, Pennsylvania, Forente stater, 15601
        • Rekruttering
        • UPMC Cancer Centers - Arnold Palmer Pavilion
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 724-838-1900
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Indiana, Pennsylvania, Forente stater, 15701
        • Rekruttering
        • IRMC Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Johnstown, Pennsylvania, Forente stater, 15901
        • Rekruttering
        • UPMC-Johnstown/John P. Murtha Regional Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 814-534-4724
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • McKeesport, Pennsylvania, Forente stater, 15132
        • Rekruttering
        • UPMC Cancer Center at UPMC McKeesport
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-647-8073
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Mechanicsburg, Pennsylvania, Forente stater, 17050
        • Rekruttering
        • UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Monroeville, Pennsylvania, Forente stater, 15146
        • Rekruttering
        • UPMC Hillman Cancer Center - Monroeville
        • Hovedetterforsker:
          • Alexander B. Olawaiye
        • Ta kontakt med:
      • Moon Township, Pennsylvania, Forente stater, 15108
        • Rekruttering
        • UPMC Hillman Cancer Center in Coraopolis
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Mount Pleasant, Pennsylvania, Forente stater, 15666
        • Rekruttering
        • UPMC Hillman Cancer Center - Part of Frick Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • N. Huntingdon, Pennsylvania, Forente stater, 15642
        • Rekruttering
        • Arnold Palmer Cancer Center Medical Oncology Norwin
        • Hovedetterforsker:
          • Alexander B. Olawaiye
        • Ta kontakt med:
      • Natrona Heights, Pennsylvania, Forente stater, 15065
        • Rekruttering
        • UPMC Cancer Center-Natrona Heights
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 724-230-3030
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • New Castle, Pennsylvania, Forente stater, 16105
        • Rekruttering
        • UPMC Hillman Cancer Center - New Castle
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Rekruttering
        • UPMC-Magee Womens Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-647-2811
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Forente stater, 15215
        • Rekruttering
        • UPMC-Saint Margaret
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-784-4900
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Forente stater, 15219
        • Rekruttering
        • UPMC-Mercy Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 800-533-8762
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Forente stater, 15237
        • Rekruttering
        • UPMC-Passavant Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-367-6454
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Forente stater, 15243
        • Rekruttering
        • UPMC-Saint Clair Hospital Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-502-3920
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Pittsburgh, Pennsylvania, Forente stater, 15232
        • Rekruttering
        • UPMC Hillman Cancer Center
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-647-8073
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Seneca, Pennsylvania, Forente stater, 16346
        • Rekruttering
        • UPMC Cancer Center at UPMC Northwest
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 814-676-7900
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • Washington, Pennsylvania, Forente stater, 15301
        • Rekruttering
        • UPMC Cancer Center-Washington
        • Ta kontakt med:
        • Hovedetterforsker:
          • Alexander B. Olawaiye
      • West Mifflin, Pennsylvania, Forente stater, 15122
        • Rekruttering
        • UPMC West Mifflin-Cancer Center Jefferson
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 412-653-8100
        • Hovedetterforsker:
          • Alexander B. Olawaiye
    • Rhode Island
      • Providence, Rhode Island, Forente stater, 02905
        • Rekruttering
        • Women and Infants Hospital
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 401-274-1122
        • Hovedetterforsker:
          • Cara A. Mathews
    • Texas
      • Dallas, Texas, Forente stater, 75390
        • Rekruttering
        • UT Southwestern/Simmons Cancer Center-Dallas
        • Ta kontakt med:
        • Hovedetterforsker:
          • David S. Miller
      • Dallas, Texas, Forente stater, 75235
        • Rekruttering
        • Parkland Memorial Hospital
        • Ta kontakt med:
        • Hovedetterforsker:
          • David S. Miller
      • Fort Worth, Texas, Forente stater, 76104
        • Suspendert
        • UT Southwestern/Simmons Cancer Center-Fort Worth
      • Richardson, Texas, Forente stater, 75080
        • Rekruttering
        • UT Southwestern Clinical Center at Richardson/Plano
        • Ta kontakt med:
        • Hovedetterforsker:
          • David S. Miller
    • Virginia
      • Charlottesville, Virginia, Forente stater, 22908
      • Richmond, Virginia, Forente stater, 23229
        • Rekruttering
        • Henrico Doctor's Hospital
        • Hovedetterforsker:
          • Andrew S. Kennedy
        • Ta kontakt med:
          • Site Public Contact
          • Telefonnummer: 804-591-4152
      • Richmond, Virginia, Forente stater, 23298
        • Aktiv, ikke rekrutterende
        • VCU Massey Comprehensive Cancer Center
    • Washington
      • Edmonds, Washington, Forente stater, 98026
        • Rekruttering
        • Swedish Cancer Institute-Edmonds
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Issaquah, Washington, Forente stater, 98029
        • Rekruttering
        • Swedish Cancer Institute-Issaquah
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Seattle, Washington, Forente stater, 98122
        • Rekruttering
        • Swedish Medical Center-First Hill
        • Hovedetterforsker:
          • Dan S. Zuckerman
        • Ta kontakt med:
      • Seattle, Washington, Forente stater, 98109
        • Aktiv, ikke rekrutterende
        • Fred Hutchinson Cancer Center
    • Wisconsin
      • Ashland, Wisconsin, Forente stater, 54806
        • Rekruttering
        • Duluth Clinic Ashland
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday
      • Ashland, Wisconsin, Forente stater, 54806
        • Rekruttering
        • Northwest Wisconsin Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Bret E. Friday

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

  • Patients with measurable or non-measurable (detectable) recurrent endometrial cancer

  • Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined per RECIST 1.1 criteria as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded). Each lesion must be >= 10 mm when measured by computed tomography (CT) or magnetic resonance imaging (MRI). Lymph nodes must be >= 15 mm in short axis when measured by CT or MRI

  • Non-measurable (detectable) disease in a patient is defined in this protocol per RECIST 1.1 criteria as one who does not have measurable disease but has at least one of the following conditions:

    • All other lesions (or sites of disease), including small lesions (longest diameter <10 mm or pathological lymph nodes with >= 10 to < 15 mm short axis), are considered non-measurable disease
    • Ascites and/or pleural effusion attributed to tumor
    • Solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions

  • Patients must have endometrial cancer with deficient mismatch repair system. All patients must have institutional immunohistochemistry (IHC) and/or microsatellite instability (MSI) testing to determine mismatch repair (MMR) status. MMR deficiency is defined as lack of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6, EPCAM) by immunohistochemistry and/or presence of microsatellite instability high using the National Cancer Institute (NCI)-5plex and Promega v1.2 assays, or institutional standards (e.g. next-generation sequencing [NGS] panel)

    • Method(s) of detection of MMR deficiency will be recorded for each patient. An institutional pathology report, and additional reports if available, documenting these results must be submitted. Patients with "equivocal" results on MMR testing by immunohistochemistry may be eligible if they have documented evidence of microsatellite instability by MSI testing or by next generation sequencing assays. MMR testing by IHC may be used to resolve equivocal/indeterminate MSI results

  • Histologic confirmation of the original primary tumor is required (submission of pathology report(s) is required). Patients with the following histologic types are eligible: Endometrioid adenocarcinoma, mucinous adenocarcinoma, dedifferentiated/undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.)

  • Patients may have received 1-2 prior lines of systemic therapy:

    • Prior anti-PD1/PD-L1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings. Patients must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition

  • Patients may have received prior radiation therapy for treatment of endometrial cancer. Prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para aortic radiation therapy, intravaginal brachytherapy, and/or palliative radiation therapy. All radiation therapy must be completed at least 4 weeks prior to registration

  • Patients may have received prior hormonal therapy for treatment of endometrial cancer. All hormonal therapy must be discontinued at least three weeks prior to registration

  • Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, biologic agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C)

  • Age >= 18

  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

  • Platelets >= 100,000/mcl

  • Absolute neutrophil count (ANC) >= 1,500/mcl

  • Creatinine =< 1.5 x institutional/laboratory upper limit of normal (ULN)

  • Total serum bilirubin level =< 1.5 x ULN (patients with known Gilbert's disease who have bilirubin level =<3 x ULN may be enrolled)

  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN

  • Adequate oxygen saturation via pulse oximeter (CTCAE v.5.0 hypoxia < grade 2 within 28 days prior to registration)

  • Thyroid-stimulating hormone (TSH) within normal limits (TSH < ULN allowed in euthyroid patients on thyroid replacement therapy). TSH testing is only required if clinically indicated

  • Patients must have recovered from effects of recent surgery, radiotherapy or chemotherapy. At least 4 weeks must have elapsed since major surgery

  • As clinically indicated, patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better and have a corrected QT (QTc) interval < 450 msec

  • The effects of nivolumab, and ipilimumab on the developing human fetus are unknown. For this reason and because nivolumab and ipilimumab are known to be teratogenic, women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 5 months after the last dose of investigational drug. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of nivolumab. Women must not be breastfeeding. Women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) do not require contraception

    • WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 55 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial

  • Patients with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression and the patient is stable off steroids for at least one month

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

  • Patients with vitiligo, endocrine deficiencies including thyroiditis managed with replacement hormones including physiologic corticosteroids are eligible

  • Patients with rheumatoid arthritis and other arthropathies, Sjogren's syndrome and psoriasis controlled with topical medication and patients with positive serology, such as antinuclear antibodies (ANA), anti-thyroid antibodies should be evaluated for the presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible

Exclusion Criteria:

  • Patients with a diagnosis of endometrial serous carcinoma or carcinosarcoma

  • Patients who received prior anti-PD1/PD-L1 therapy and had grade 3-4 or recurring grade 2 immune-related toxicities that led to dose delay or discontinuation of immunotherapy due to those toxicities

  • Patients who received anti-CTLA-4 therapy or other immunotherapeutic agents

  • Patients on chronic steroid therapy except those on replacement therapy at a daily dose of 10mg or less prednisone or equivalent

  • Patients on immunosuppressive therapy, with the exception of:

    • Intra-nasal, inhaled, topical or local steroid injections
    • Premedication for hypersensitivity reaction

  • Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded. These include but are not limited to patients with a history of immune related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, myasthenia gravis; systemic autoimmune disease such as systemic lupus erythematosus (SLE), connective tissue diseases, scleroderma, inflammatory bowel disease (IBD), Crohn's, ulcerative colitis, hepatitis; and patients with a history of toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome should be excluded because of the risk of recurrence or exacerbation of disease

  • Patients with known immune impairment who may be unable to respond to anti-CTLA-4 antibody

  • Patients with uncontrolled intercurrent illness including, but not limited to: ongoing or active infection (except for uncomplicated urinary tract infection), interstitial lung disease or active, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Women who are pregnant or unwilling to discontinue nursing

  • Prior therapy with CTLA-4 inhibitors, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab, and/or ipilimumab including severe hypersensitivity reactions to any monoclonal antibody

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm I (nivolumab and ipilimumab)

Patients receive nivolumab IV over 30 minutes on day 1 of each cycle and ipilimumab IV over 90 minutes on day 1 of every other cycle. Cycles repeat every three weeks. Treatment with nivolumab and ipilimumab repeats for up to 8 cycles in the absence of disease progression, unacceptable toxicity, or CR. Patients then receive nivolumab alone on day 1 of each cycle. Cycles repeat every 4 weeks in the absence of disease progression, unacceptable toxicity, or CR.

MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.

Additionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial.
Biologisk: Ipilimumab

Given IV

Andre navn:
  • Anti-cytotoksisk T-lymfocytt-assosiert antigen-4 monoklonalt antistoff
  • BMS-734016
  • Ipilimumab Biosimilar CS1002
  • MDX-010
  • MDX-CTLA4
  • Yervoy
  • MDX010
  • BMS734016
  • BMS 734016
  • MDX 010
Fremgangsmåte: Computed Tomography

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype
Fremgangsmåte: Magnetic Resonance Imaging

Undergo MRI

Andre navn:
  • MR
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medisinsk bildebehandling, magnetisk resonans / kjernemagnetisk resonans
  • MR Imaging
  • MR-skanning
  • NMR-avbildning
  • NMRI
  • Kjernemagnetisk resonansavbildning
  • Magnetisk resonanstomografi (MR)
  • sMRI
  • Magnetisk resonansavbildning (prosedyre)
  • MR-er
  • Strukturell MR
Biologisk: Nivolumab

Given IV

Andre navn:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Fremgangsmåte: Biospecimen Collection

Undergo collection of tissue and/or blood samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling
Aktiv komparator: Arm II (nivolumab)

Patients receive nivolumab IV over 30 minutes on day 1 of each cycle. Treatment repeats every 3 weeks for up to 8 cycles, then every 4 weeks thereafter in the absence of disease progression, unacceptable toxicity, or CR.

MAINTENANCE THERAPY: Patients achieving CR receive nivolumab for an additional 12 months in the absence of disease progression or unacceptable toxicity.

Additionally, patients may optionally undergo collection of tissue samples on study as well as blood samples throughout the trial. Patients also undergo CT scan and/or MRI throughout the trial.
Fremgangsmåte: Computed Tomography

Undergo CT

Andre navn:
  • CT
  • KATT
  • CAT-skanning
  • Beregnet aksial tomografi
  • Datastyrt aksialtomografi
  • Datastyrt tomografi
  • CT skann
  • tomografi
  • Datastyrt aksial tomografi (prosedyre)
  • Datastyrt tomografi (CT) skanning
  • Diagnostisk CAT -skanning
  • Diagnostisk CAT -skannertype
Fremgangsmåte: Magnetic Resonance Imaging

Undergo MRI

Andre navn:
  • MR
  • Magnetisk resonans
  • Magnetic Resonance Imaging Scan
  • Medisinsk bildebehandling, magnetisk resonans / kjernemagnetisk resonans
  • MR Imaging
  • MR-skanning
  • NMR-avbildning
  • NMRI
  • Kjernemagnetisk resonansavbildning
  • Magnetisk resonanstomografi (MR)
  • sMRI
  • Magnetisk resonansavbildning (prosedyre)
  • MR-er
  • Strukturell MR
Biologisk: Nivolumab

Given IV

Andre navn:
  • BMS-936558
  • MDX-1106
  • NIVO
  • ONO-4538
  • Opdivo
  • CMAB819
  • Nivolumab Biosimilar CMAB819
  • MDX 1106
  • MDX1106
  • BMS 936558
  • ABP 206
  • Nivolumab Biosimilar ABP 206
  • BCD-263
  • Nivolumab Biosimilar BCD-263
  • BMS936558
  • ONO 4538
  • ONO4538
Fremgangsmåte: Biospecimen Collection

Undergo collection of tissue and/or blood samples

Andre navn:
  • Biologisk prøvesamling
  • Bioprøve samlet
  • Prøvesamling

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-free survival (PFS)
Tidsramme: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years after randomization

The statistical test used for decision making is the stratified, standardized log-rank test (Z) based on PFS. For the safety lead-in analysis, the primary endpoint is the observation of at least one dose-limiting toxicity (DLT) in the first 3 cycles of treatment. Patients are classified as having a DLT in 3 cycles or receiving adequate treatment.
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed up to 5 years after randomization

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Overall survival (OS)
Tidsramme: Up to 5 years after randomization

Will be assessed when the PFS data are mature. The null hypothesis will be that the hazard of death in regimen 1 is equal to the hazard of death in regimen 2. That is, Ho: HR = 1.00. The alternative will be that Ha: HR < 1.00 (regimen 1 to 2). The number of deaths is unknown.
Up to 5 years after randomization
Objective tumor response (ORR)
Tidsramme: Up to 5 years after randomization

Defined as the frequency of patients who have either a partial or complete response by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The number of patients with responses will be tabulated by the treatment they were randomized to. Fisher's Exact Test will be used to test the hypothesis that the probabilities of response in each arm is the same. ORR will be evaluated only in patients who had measurable disease per RECIST 1.1 before starting treatment.
Up to 5 years after randomization
Progression-free survival (PFS) at 6 months
Tidsramme: From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 6 months after randomization

A patient who survives at least 6 months progression-free will be considered to have had a successful outcome. Those who progress or die within 6 months are considered treatment failures, and those who survive progression-free for less than 6 months will be considered to have an unknown outcome or indeterminate. If the patient's status cannot be determined, she will be moved to the "failure" status for analysis. Like tumor response, the hypothesis of equivalent probabilities will be assessed with Fisher's Exact Test.
From study entry to time of progression or death, whichever occurs first, or date of last contact if neither progression nor death has occurred, assessed at 6 months after randomization
Incidence of adverse events
Tidsramme: Up to 5 years after randomization

Will be assessed by Common Terminology Criteria for Adverse Events (CTCAE). Will be tabulated by frequency and severity by treatment regimen. The treatment regimens will be compared by classifying the toxicities as severe or not and tested for equivalent probabilities by Fisher's Exact Test or whether the estimated probabilities of severe toxicities diverge by more than 10%.
Up to 5 years after randomization

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

National Cancer Institute (NCI)

Samarbeidspartnere

NRG Oncology

Etterforskere

  • Hovedetterforsker: Haider S Mahdi, NRG Oncology

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. juni 2022

Primær fullføring (Antatt)

30. juli 2032

Studiet fullført (Antatt)

30. juli 2032

Datoer for studieregistrering

Først innsendt

6. november 2021

Først innsendt som oppfylte QC-kriteriene

6. november 2021

Først lagt ut (Faktiske)

9. november 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

2. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

30. oktober 2026

Sist bekreftet

1. juni 2026

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • NCI-2021-11881
  • U10CA180868 (U.S. NIH-stipend/kontrakt)
  • NCI-2021-11881 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
  • NRG-GY025 (Annen identifikator: CTEP)
  • NRG-GY025 (Annen identifikator: NRG Oncology)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere